1. Search Result
Search Result
Results for "

Trypanosoma brucei brucei 427

" in MedChemExpress (MCE) Product Catalog:

203

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

39

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125731
    Glycodeoxycholic acid
    3 Publications Verification

    Endogenous Metabolite STAT Autophagy Inflammation/Immunology Cancer
    Glycodeoxycholic Acid is a natural product found in Streptomyces nigricans, Trypanosoma brucei and C. elegans. Glycodeoxycholic Acid induces hepatocyte necrosis and autophagy in patients with obstructive cholestasis .
    Glycodeoxycholic acid
  • HY-12054
    Hesperadin
    Maximum Cited Publications
    12 Publications Verification

    Aurora Kinase Autophagy Influenza Virus Parasite Cancer
    Hesperadin is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin inhibits Aurora B with an IC50 of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis. Hesperadin also is a broad-spectrum influenza antiviral .
    Hesperadin
  • HY-103056
    DDD85646
    1 Publications Verification

    IMP-366

    DNA/RNA Synthesis Parasite Infection
    DDD85646 (IMP-366) is an orally active of trypanosoma brucei N-myristoyltransferase (TbNMT IC50=2 nM; hNMT IC50=4 nM). The enzyme N-myristoyltransferase (NMT) is a potential agent target for human African trypanosomiasis .
    DDD85646
  • HY-128170

    Parasite Infection
    Ebsulfur is a benzisothiazolone cytocidal inhibitor targeting the trypanothione reductase (TryR) of Trypanosoma brucei, with IC50 values of 61-293 nM for Trypanosoma brucei. Ebsulfur can be used for the research of African trypanosomiasis .
    Ebsulfur
  • HY-153021

    Parasite Infection
    NMT-IN-1 is a Trypanosoma brucei N-myristoyltransferase (TbNMT) inhibitor, with an IC50 of 31 μM against TbNMT and an IC50 of 66 μM against hNMT. As a thiazolidinone hit compound identified via virtual screening, NMT-IN-1 exerts enzymatic inhibitory effects by binding to the active site of TbNMT. NMT-IN-1 adopts a binding mode distinct from that of pyrazole sulfonamide inhibitors and can inhibit the myristoyl transfer reaction catalyzed by TbNMT. NMT-IN-1 is mainly used in the research of anti-parasitic lead compounds for human African trypanosomiasis (African sleeping sickness). It provides a structural basis for the subsequent optimization of TbNMT inhibitors with high activity, high selectivity and blood-brain barrier permeability .
    NMT-IN-1
  • HY-N7266
    Obtusifoliol
    1 Publications Verification

    Cytochrome P450 Parasite Infection Cancer
    Obtusifoliol is a specific CYP51 inhibitor, Obtusifoliol shows the affinity with Kd values of 1.2 μM and 1.4 μM for Trypanosoma brucei (TB) and human CYP51, respectively .
    Obtusifoliol
  • HY-136637

    Phosphodiesterase (PDE) Parasite Infection
    NPD-001 is a potent Trypanosoma brucei phosphodiesterases 1/2 (TbrPDEB1/2) inhibitor, with IC50 values of 4 and 3 nM, respectively. NPD-001 also inhibits hPDE4. NPD-001 can increase cAMP levels in parasites, prevent cytokinesis, and cause the parasites to form multinucleated, multi-flagellated cells that eventually lyse. NPD-001 can be used for the research of infection .
    NPD-001
  • HY-101015A

    Phospholipase Apoptosis Inflammation/Immunology
    OBAA is a potent phospholipase A2 (PLA2) inhibitor with an IC50 of 70 nM. OBAA blocks Melittin-induced Ca 2+ influx in Trypanosoma brucei with an IC50 of 0.4 μM .
    OBAA
  • HY-21496

    4-Carboxybenzyl bromide

    Parasite Infection
    4-(Bromomethyl)benzoic acid (4-Carboxybenzyl bromide) is an antiparasitic agent with low activity against Leishmania amazonensis and Trypanosoma cruzi. 4-(Bromomethyl)benzoic acid has certain cytotoxicity to PBMCs, with an IC50 of 88.8 μM .
    4-(Bromomethyl)benzoic acid
  • HY-162066

    Parasite Infection
    DNDI-6174 is an orally active Leishmania cytochrome b (Qi site of cytochrome bc1 complex/complex III) inhibitor. DNDI-6174 binds to the Qi site of Leishmania cytochrome b, inhibits cytochrome bc1 complex activity in the parasite's electron transport chain across promastigote and axenic amastigote stages. DNDI-6174 reduces parasite burden in rodent models, inhibits growth of various Leishmania species, drug-resistant clinical isolates, and Trypanosoma cruzi, with marginal activity against Trypanosoma brucei. DNDI-6174 can be used for the research of visceral leishmaniasis, cutaneous leishmaniasis .
    DNDI-6174
  • HY-12607

    Parasite Infection
    ML251, a potent nanomolar T. brucei and T. cruzi phosphofructokinase (PFK) inhibitor, inhibits T. brucei PFK (IC50=0.37 μM) and T. cruzi PFK (IC50=0.13 μM). ML251 can be used for the research of parasite .
    ML251
  • HY-125731R

    Reference Standards Endogenous Metabolite STAT Autophagy Inflammation/Immunology Cancer
    Glycodeoxycholic Acid (Standard) is the analytical standard of Glycodeoxycholic Acid. This product is intended for research and analytical applications. Glycodeoxycholic Acid is a natural product found in Streptomyces nigricans, Trypanosoma brucei and C. elegans. Glycodeoxycholic Acid induces hepatocyte necrosis and autophagy in patients with obstructive cholestasis .
    Glycodeoxycholic Acid (Standard)
  • HY-108938

    Cytochrome P450 Fungal Parasite Infection
    SDZ285428 is a CYP51 inhibitor. SDZ285428 inhibits Trypanosoma cruzi (TC) CYP51 with I/E2 <1 (5 min) and I/E2=9 (1 h). SDZ285428 inhibits Trypanosoma brucei (TB) CYP51 with I/E2 <1 (5 min) and I/E2=35 (1 h) .
    SDZ285428
  • HY-111759
    Jaspamycin
    1 Publications Verification

    7-CN-7-C-Ino

    PKA Parasite Infection
    Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC50 of 6.5 nM and Kd of 8 nM in Trypanosoma brucei. Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα. Anti-parasite activity .
    Jaspamycin
  • HY-153238

    Parasite mRNA Infection
    AN15368 is an orally active trypanocidal agent and a prodrug of AN14667. AN15368 selectively targets CPSF3-mediated mRNA maturation in intracellular amastigotes of Trypanosoma cruzi, reducing the mRNA levels of the parasite. As a prodrug, AN15368 can be cleaved into its active carboxylate form by CBP of Trypanosoma cruzi. AN15368 completely clears long-term naturally acquired Trypanosoma cruzi infections in non-human primates. AN15368 can be used in the research of Chagas disease .
    AN15368
  • HY-155655

    Parasite Infection
    JC-229 is a TbRPA1 inhibitor. JC-229 targets RPA1 in Trypanosoma brucei. JC-229 can be used for the research of Human African Trypanosomiasis (HAT) .
    JC-229
  • HY-135562

    Parasite Antibiotic Infection Cancer
    Ascofuranone is an orally active inhibitor of Trypanosoma brucei brucei (TAO) with a Ki value of 2.38 nM. Ascofuranone inhibits IGF-1-induced cancer cell migration, invasion, motility and actin cytoskeleton formation, and exerts anti-tumor effects. Ascofuranone can be used in research related to tumor metastasis, African trypanosomiasis, bacterial infections, lung cancer and hepatocellular carcinoma .
    Ascofuranone
  • HY-169728

    Hexokinase Parasite Infection
    SID 24785302 is a hexokinase inhibitor with antiparasitic activity. SID 24785302 exhibits activity against T. brucei and Leishmania. SID 24785302 can be used for the research of mitochondrial DNA disorders and parasitic infection .
    SID 24785302
  • HY-W043676

    Parasite Drug Intermediate Infection
    Dibenzosuberol (Compound 2) is a key intermediate in the synthesis of compounds associated with inhibiting Trypanosoma thiol reductase (TryR). Dibenzosuberol also shows inhibition of T. brucei with an EC50 value of 51.3 μM. Dibenzosuberol is also an impurity of Amitriptyline (HY-B0527) .
    Dibenzosuberol
  • HY-103033

    Parasite Infection
    T.cruzi-IN-1 is a potent Trypanosoma cruzi inhibitor with an IC50 of 8 nM. T.cruzi-IN-1, a 4-trifluoromethyl substituted analog, has the potential for both the acute and chronic stages of Chagas disease .
    T.cruzi-IN-1
  • HY-W973644

    Mitochondrial Metabolism Parasite Infection
    LY-266500 is a succinyl CoA synthetase (SCS) specific inhibitor. LY-266500 has inhibitory effects on various parasites, such as Trypanosoma brucei brucei (IC50 =0.6 μM) and Leishmania donovani (IC50 =2.86 μM). LY-266500 can be used for research on parasitic infections .
    LY-266500
  • HY-179690

    Parasite Adenosine Kinase Infection
    Antiparasitic agent-30 is a potent adenosine kinase TbrAK modulator and antitrypanosomal agent. Antiparasitic agent-30 exhibits significant inhibitory activity against Trypanosoma brucei rhodesiense, while enhancing the activity of recombinant TbrAK(EC50=38 nM, Ka=75 nM-497 nM). Antiparasitic agent-30 exerts its pharmacological effects by eliminating intrinsic substrate inhibition and hyperactivating TbrAK in Trypanosoma brucei rhodesiense. Antiparasitic agent-30 serves as a valuable tool molecule for studying acute African human trypanosomiasis (sleeping sickness) .
    Antiparasitic agent-30
  • HY-N2656

    Parasite Infection
    5,7,8-Trimethoxycoumarin is an anti-parasite agent with IC50s of 25.5 μM and 57.7 μM against Trypanosoma cruzi and L. amazonensis, respectively .
    5,7,8-Trimethoxycoumarin
  • HY-16121

    Cathepsin Others
    CAA-0225 is a tissue protease L inhibitor that inhibits rat liver tissue protease L with a IC50 value of 1.9 nM. CAA-0225 can participate in the degradation of autophagosome membrane markers LC3-II and GABARAP (HY-P72639), improve cardiac function in mice with reperfusion injury, and kill and eliminate Trypanosoma brucei parasites [1][2][3].
    CAA-0225
  • HY-136200

    Parasite Infection
    Antitrypanosomal agent 2 is a potent and selective trypanosoma brucei inhibitor .
    Antitrypanosomal agent 2
  • HY-118996A

    Parasite Infection
    Isometamidium chloride is an antiprotozoal agent, that exhibits activity against trypanosome. Isometamidium chloride can be used in research of african sleeping sickness .
    Isometamidium chloride
  • HY-W009689

    Parasite Infection
    TbPTR1 inhibitor 2 (Compound 3a) is a PTR1 enzyme inhibitor, with IC50s of 34.2 and 32.9 μM for TbPTR1 and LmPTR1. TbPTR1 inhibitor 2 has anti-parasitic activity against T. brucei (IC50: 34.2 μM) .
    TbPTR1 inhibitor 2
  • HY-101015

    Phospholipase Apoptosis Inflammation/Immunology
    (2E)-OBAA is a potent phospholipase A2 (PLA2) inhibitor, with an IC50 of 70 nM. (2E)-OBAA induces apoptosis of HUVEC cells. (2E)-OBAA blocks Melittin-induced Ca 2+ influx in Trypanosoma brucei, with an IC50 of 0.4 μM .
    (2E)-OBAA
  • HY-147765

    Parasite Infection
    Anti-Trypanosoma cruzi agent-3 (Compound 7c) is an antiprotozoal agent .
    Anti-Trypanosoma cruzi agent-3
  • HY-125632

    Parasite Infection
    Ro 19-9638 is the major metabolite of Ro 15-0216. Ro 19-9638 exhibits antiparasitic efficacy against Trypanosoma brucei rhodesiense with an IC50 of 0.0341 µg/mL .
    Ro 19-9638
  • HY-168538

    Paraptosis Infection
    Antitrypanosomal agent 21 (Compound C-1) is a trypanosoma brucei inhibitor. Antitrypanosomal agent 21 decreases the level of D6XM23 in parasite lysates .
    Antitrypanosomal agent 21
  • HY-147933

    Parasite Infection
    Antitrypanosomal agent 8 (compound 3b) has potent antitrypanosomal activity against Trypanosoma brucei with an IC50 value of 0.79 μM and exhibits certain cytotoxicity in L6 cells (IC50=80.95 μM) .
    Antitrypanosomal agent 8
  • HY-147940

    Parasite Infection
    TbPTR1 inhibitor 1 (compound 5d) is a potent kinetoplastid pteridine reductase 1 (PTR1) inhibitor with an IC50<0.1 nM for TbPTR1. TbPTR1 inhibitor 1 has inhibitory activity against Trypanosoma brucei (EC50=0.66 μM) .
    TbPTR1 inhibitor 1
  • HY-N16437

    Parasite Infection
    Panowamycin A is an isochroman compound that can be produced by Streptomyces sp. K07-0010. Panowamycin A exhibits antitrypanosomal activity against the Trypanosoma brucei brucei GUTat 3.1 strain (IC50: 0.40 μg/mL). Panowamycin A shows weak cytotoxicity towards human fetal lung fibroblast MRC-5 cells (IC50: 2.95 μg/mL). Panowamycin A can be used for research in the field of antitrypanosomal studies .
    Panowamycin A
  • HY-170363

    Proteasome Parasite Infection
    Proteasome-IN-6 (Compound J-80) inhibits the β5 catalytic subunit of the Trypanosoma brucei 20S proteasome, inibits T. b. brucei, T. b. gambiense and T. b. rhodesiense with EC50s of 157 nM, 220 nM and 156 nM, respectively. Proteasome-IN-6 exhibits antitrypanosomal activity in mouse model .
    Proteasome-IN-6
  • HY-168342

    Parasite Infection
    Anti-Trypanosoma cruzi agent-6 (Compound 8) exhibits inhibitory activity against Trypanosoma cruzi, that inhibits the epimastigote, trypomastigote and amastigote form of T. cruzi with IC50s of 24.7 µM, 1.8 µM and 1.6 µM, respectively .
    Anti-Trypanosoma cruzi agent-6
  • HY-162656

    Dihydrofolate reductase (DHFR) Infection
    DHFR-IN-19 (Compound 2g) is a selective inhibitor for TbDHFR with Ki of 9 nM. DHFR-IN-19 exhibits antiparasitic activity against Trypanosoma brucei with an EC50 of 14.5 μM .
    DHFR-IN-19
  • HY-175517

    Parasite Infection
    PEX5-PEX14 PPI-IN-3 (Compound 7) is an inhibitor of the PEX5-PEX14 protein-protein interaction (PPI) with an EC50 of 95 μM. PEX5-PEX14 PPI-IN-3 has an EC50 of 7.2 μM against Trypanosoma brucei (T. brucei). PEX5-PEX14 PPI-IN-3 exhibits low cytotoxicity towards HepG2 cells and possesses antiparasitic activity .
    PEX5-PEX14 PPI-IN-3
  • HY-115972

    Parasite Infection Inflammation/Immunology
    Anti-Trypanosoma cruzi agent-1 (Compd 3b), selective compound against NINOA trypomastigote (IC50 = 0.51 µM) and INC-5 epimastigote form (IC50 = 3.06 µM), posseses anti-T. gondii activity .
    Anti-Trypanosoma cruzi agent-2
  • HY-111906

    Cytochrome P450 Parasite Infection
    SCYX-6759 is an orally active, blood-brain barrier permeable anti-T. brucei agent. SCYX-6759 inhibits cytochrome P450 (IC50s: 30.3, 30.6, 47.4 μM for 2D6, 2C9, 2C19, respectively.) SCYX-6759 exhibits potent activity against T. b. brucei 427, T. b. rhodesiense STIB900, and T. b. gambiense STIB930, with IC50s of 0.07, 0.038 and 0.030 μg/mL, respectively .
    SCYX-6759
  • HY-116045

    Parasite Cancer
    PDEB1-IN-1 (Compound 12b) is the derivative of Cilomilast (HY-10790), and serves as an inhibitor for TryPanosoma Brucei PDEB1 (TbrPDEB1) with an IC50 of 0.95 μM. PDEB1-IN-1 inhibits the proliferation of T. Brucei with an EC50 of 26 μM .
    PDEB1-IN-1
  • HY-148323

    Parasite Infection
    Anti-Trypanosoma cruzi agent-4 (compound 5c) is an inhibitor of Trypanosoma cruzi. Anti-Trypanosoma cruzi agent-4 can be used for the research of infection .
    Anti-Trypanosoma cruzi agent-4
  • HY-173461

    Parasite Infection
    Anti-Trypanosoma cruzi agent-7 (compound 1) is a potent Trypanosoma cruzi inhibitor with an EC50 of 1.26 µM. Anti-Trypanosoma cruzi agent-7 can be used in the study of Chagas disease .
    Anti-Trypanosoma cruzi agent-7
  • HY-116004

    Parasite Infection
    Anti-Trypanosoma cruzi agent-5 (compoung 8) is a potent inhibitor of Trypanosoma cruzi proliferation .
    Anti-Trypanosoma cruzi agent-5
  • HY-147549

    Parasite Infection
    Antitrypanosomal agent 6 (compound 18a) is a potent and antitrypanosomal agent with favorable ADME properties. Antitrypanosomal agent 6 is > 2-fold more potent against Trypanosoma brucei (T. brucei) than Nifurtimox, with an IC50 value of 0.47 μM. Antitrypanosomal agent 6 has strong interaction to DNA and can bind with high selectivity to AT-rich DNA .
    Antitrypanosomal agent 6
  • HY-147550

    Parasite Infection
    Antitrypanosomal agent 7 (compound 18c) is a potent and antitrypanosomal agent with favorable ADME properties. Antitrypanosomal agent 7 is > 2-fold more potent against Trypanosoma brucei (T. brucei) than Nifurtimox, with an IC50 value of 0.71 μM. Antitrypanosomal agent 7 has strong interaction to DNA and can bind with high selectivity to AT-rich DNA .
    Antitrypanosomal agent 7
  • HY-115971

    Parasite Infection Inflammation/Immunology
    Anti-Trypanosoma cruzi agent-1 (Compd E5) posseses anti-T. gondii activity .
    Anti-Trypanosoma cruzi agent-1
  • HY-144296

    Parasite Infection
    Purine phosphoribosyltransferase-IN-2 is a potent inhibitor of the Plasmodium falciparum ((Pf)), Plasmodium vivax ((Pv)) and Trypanosoma brucei ((Tbr)) 6-oxopurine phosphoribosyltransferase (PRT), with Kis of 30, 20 and 2 nM, respectively .
    Purine phosphoribosyltransferase-IN-2
  • HY-119938

    Bacterial Infection
    Tuberculosis inhibitor 1 is a potent and non-cytotoxic trypanosoma brucei growth inhibitor with an EC50 of 5 nM .
    Tuberculosis inhibitor 1
  • HY-N3247

    Parasite Others
    Monomethyl kolavate is a Trypanosoma brucei GAPDH enzyme (TbGAPDH) inhibitor with theIC50 value of 2 µM .
    Monomethyl kolavate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: